From the publishers of JADPRO

MPN Resource Center

Advertisement

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project

Last Updated: Wednesday, March 1, 2023

Data from a retroprospective, observational real-life study of 154 patients with myelofibrosis treated with ruxolitinib show that larger splenomegaly and delayed treatment initiation correlated with lower spleen response at 24 weeks, in addition to spleen response being associated with a superior overall survival.

Cancer Medicine
Advertisement
News & Literature Highlights
Advertisement
Advertisement